New Evidence With BTK Inhibitor Therapy in CLL and MCL From SOHO 2023

In this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at SOHO 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of: 

• Matching-adjusted indirect comparison of 3 randomized phase III trials of ibrutinib for relapsed/refractory CLL 
• Meta-analysis of cardiovascular adverse events with second-generation BTK inhibitors in CLL 
• BRUIN: updated results of pirtobrutinib in covalent BTK inhibitor–pretreated MCL
• ViPOR: venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide for relapsed/refractory and treatment-naive MCL

Presenters:

Catherine C. Coombs, MD, MS
Associate Clinical Professor
Division of Hematology/Oncology, Department of Medicine
UCI Health
Orange, California

Toby Eyre, MBChB, MD
Honorary Senior Lecturer
Hematology and Cancer
University of Oxford
Consultant Hematologist
Department of Hematology
Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.